It is important to note that tau vaccines and antisense oligonucleotides (e.g., BIIB080) have the potential to reduce pathologic tau burden and slow cognitive decline in early trials, and other investigational treatments such as synaptic modulators, neuroprotectants, metabolic modulators, and anti-inflammatory drugs are changing the landscape of AD treatment (118). Here, MAPT is linked to Mental deterioration.